Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
2024's Driving Clearing Robots: Master Suggestions and Surveys - 2‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- 3Underestimated Metropolitan Experience Urban communities On the planet
- 4the 6 Shrewd Beds for seniors: A Complete Survey
- 5The Following Huge Thing: 5 Progressive Tech New businesses
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- Scientists document a death from a meat allergy tied to certain ticks
- You finally got a doctor's appointment. Here's how to get the most out of it
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
- 80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
- Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
- Figure out how to Guarantee Your Dental Embeds Endure forever
